P53-miR-191-SOX4 regulatory loop affects apoptosis in breast cancer
Autor: | Prahlad C. Ghosh, Ritu Kulshreshtha, Neha Nagpal, Shivani Sharma |
---|---|
Rok vydání: | 2017 |
Předmět: |
0301 basic medicine
Caspase 3 Drug resistance Biology medicine.disease 03 medical and health sciences SOX4 030104 developmental biology 0302 clinical medicine Breast cancer Annexin Apoptosis 030220 oncology & carcinogenesis microRNA medicine Cancer research Doxorubicin Molecular Biology medicine.drug |
Zdroj: | RNA. 23:1237-1246 |
ISSN: | 1469-9001 1355-8382 |
Popis: | miRNAs have emerged as key participants of p53 signaling pathways because they regulate or are regulated by p53. Here, we provide the first study demonstrating direct regulation of an oncogenic miRNA, miR-191-5p, by p53 and existence of a regulatory feedback loop. Using a combination of qRT-PCR, promoter-luciferase, and chromatin-immunoprecipitation assays, we show that p53 brings about down-regulation of miR-191-5p in breast cancer. miR-191-5p overexpression brought about inhibition of apoptosis in breast cancer cell lines (MCF7 and ZR-75) as demonstrated by reduction in annexin-V stained cells and caspase 3/7 activity, whereas miR-191-5p down-regulation showed the opposite. We further unveiled that SOX4 was a direct target of miR-191-5p. SOX4 overexpression was shown to increase p53 protein levels in MCF7 cells. miR-191-5p overexpression brought about down-regulation of SOX4 and thus p53 levels, suggesting the existence of a regulatory feedback loop. Breast cancer treatment by doxorubicin, an anti-cancer drug, involves induction of apoptosis by p53; we thus wanted to check whether miR-191-5p affects doxorubicin sensitivity. Interestingly, Anti-miR-191 treatment significantly decreased the IC50 of the doxorubicin drug and thus sensitized breast cancer cells to doxorubicin treatment by promoting apoptosis. Overall, this work highlights the importance of the p53-miR-191-SOX4 axis in the regulation of apoptosis and drug resistance in breast cancer and offers a preclinical proof-of-concept for use of an Anti-miR-191 and doxorubicin combination as a rational approach to pursue for better breast cancer treatment. |
Databáze: | OpenAIRE |
Externí odkaz: |